Micro-k 10 Extencaps
NDC Package 64011-009-08

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Micro-k 10 Extencaps is bECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. Marketed by Ther-rx Corporation, this product is identified by NDC 64011-009 and is authorized under FDA application NDA018238.

Identification & Billing

NDC Package Code
64011-009-08
Package Description
500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
Product Code
64011-009
11-Digit Billing Format
64011000908
RxNorm Crosswalk
  • RxCUI: 208939 - Micro-K Extencaps 8 MEQ Extended Release Oral Capsule
  • RxCUI: 208939 - potassium chloride 8 MEQ Extended Release Oral Capsule [Micro-K]
  • RxCUI: 208939 - K+ Chloride 8 MEQ Extended Release Oral Capsule [Micro-K]
  • RxCUI: 208939 - Micro-K 8 MEQ Extended Release Oral Capsule
  • RxCUI: 208939 - Pot Chloride 8 MEQ Extended Release Oral Capsule [Micro-K]

Clinical Specifications

Proprietary Name
Micro-k 10 Extencaps
Dosage Form
-
Usage Information
BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated.

Regulatory & Marketing

Labeler Name
Ther-rx Corporation
FDA Application #
NDA018238
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-01-2009
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (64011-009). Click a package code to view its specific billing and regulatory data.

64011-009-04
100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
64011-009-11
100 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 64011-009-08 identifies a specific commercial package of 500 capsule, extended release in 1 bottle of Micro-k 10 Extencaps, labeled by Ther-rx Corporation. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Ther-rx Corporation on August 01, 2009. The current certification is valid through December 31, 2017.

How is this Ther-rx Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 64011000908. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
64011-009-08
11-Digit CMS (5-4-2)
64011-0009-08

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.